Apellis Pharmaceuticals Inc (APLS)
28.52
+0.54
(+1.93%)
USD |
NASDAQ |
Nov 04, 16:00
29.48
+0.96
(+3.37%)
After-Hours: 06:24
Apellis Pharmaceuticals Cash from Investing (Quarterly): -0.09M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -0.09M |
| March 31, 2024 | -0.293M |
| December 31, 2023 | 0.004M |
| September 30, 2023 | -0.047M |
| June 30, 2023 | -0.372M |
| March 31, 2023 | -0.259M |
| December 31, 2022 | 124.13M |
| September 30, 2022 | 124.78M |
| June 30, 2022 | 82.93M |
| March 31, 2022 | -271.95M |
| December 31, 2021 | 84.98M |
| September 30, 2021 | 179.65M |
| June 30, 2021 | 129.75M |
| Date | Value |
|---|---|
| March 31, 2021 | -146.76M |
| December 31, 2020 | -0.091M |
| September 30, 2020 | 198.76M |
| June 30, 2020 | -287.81M |
| March 31, 2020 | -227.85M |
| December 31, 2019 | -0.155M |
| September 30, 2019 | -0.471M |
| June 30, 2019 | -0.192M |
| March 31, 2019 | -0.875M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-287.81M
Minimum
Jun 2020
198.76M
Maximum
Sep 2020
-0.5627M
Average
-0.09M
Median
Jun 2024
Cash from Investing (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | -16.16M |
| Ionis Pharmaceuticals Inc | 62.45M |
| EyePoint Pharmaceuticals Inc | -160.40M |
| Cassava Sciences Inc | -0.029M |
| Macrogenics Inc | 47.44M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -8.339M |
| Cash from Financing (Quarterly) | 42.49M |
| Free Cash Flow | -408.81M |
| Free Cash Flow Per Share (Quarterly) | -0.068 |
| Free Cash Flow to Equity (Quarterly) | -372.53M |
| Free Cash Flow to Firm (Quarterly) | -2.235M |
| Free Cash Flow Yield | -11.74% |